NTLA stock forecast, quote, news & analysis
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics... Show more
Intellia Therapeutics (NTLA) Stock Analysis: Pipeline Wins Fuel Momentum
Key Takeaways
- Intellia Therapeutics' shares have climbed in recent weeks amid positive regulatory developments for its CRISPR-based therapies.
- FDA lifted clinical holds on key Phase 3 trials, boosting investor confidence in the gene-editing pipeline.
- Analysts raised price targets following pipeline progress, with a consensus leaning toward buy ratings.
- Q4 2025 earnings beat expectations, supporting a strong cash position into 2026.
- 2026 poised as pivotal for Phase 3 data readouts in ATTR amyloidosis and hereditary angioedema programs.
Current Market Snapshot
Intellia Therapeutics (NTLA) has shown notable resilience in recent trading sessions, reflecting heightened interest in its CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing platform. The stock has experienced upward momentum over recent weeks, driven by regulatory clearances and pipeline advancements, despite the inherent volatility typical of clinical-stage biotechs. Trading within a broad 52-week range, NTLA maintains a market capitalization around $1.8 billion, with elevated volumes signaling active investor engagement. Broader biotech sector tailwinds and positive analyst revisions have contributed to this cycle's strength, positioning the shares for continued scrutiny amid upcoming milestones.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available on the platform, which collectively trade thousands of tickers across diverse strategies and timeframes. These bots employ approaches like swing trading, trend following, dip hunting, and take-profit/stop-loss corridors (e.g., TP 3%/SL 2%), delivering impressive stats such as annualized returns ranging from +15% to +170%, win rates of 48% to 88%, and profit factors up to 11.7. Focused on sectors including semiconductors, industrials, energy, and aerospace, they offer real-time signals for copy trading with average trade durations of hours to weeks and strong risk-adjusted metrics like profit-to-drawdown ratios exceeding 20 in top performers. Explore these bots to identify those aligning with current market dynamics and enhance your trading edge.
Recent Developments Driving NTLA Price Action
In the past 30 days, Intellia Therapeutics (NTLA) has benefited from several catalysts reinforcing its position in the CRISPR gene-editing space. A pivotal event was the U.S. Food and Drug Administration (FDA) lifting the clinical hold on the MAGNITUDE Phase 3 trial for nex-z (nexiguran zaldlisiran), an investigational in vivo CRISPR-based therapy targeting transthyretin amyloid cardiomyopathy (ATTR-CM), announced on March 2, 2026. This regulatory green light, following earlier safety concerns including a patient death in a prior study, enabled resumption of dosing and sparked a premarket surge in shares, underscoring investor optimism about the program's potential as a one-time treatment.
The positive momentum carried into analyst actions, with multiple firms adjusting targets upward in early March. Jones Trading upgraded NTLA to Buy with a $29 price target on March 4, while Leerink Partners, Canaccord Genuity, RBC Capital, and Wells Fargo raised targets and maintained favorable ratings like Outperform and Buy. Bank of America reaffirmed Hold on March 24, but the consensus tilts overweight with an average target around $25. These revisions reflected confidence in pipeline execution, contributing to a roughly 20% stock rise over the prior three months as of mid-April.
Echoing earlier Q4 2025 financials released February 26—which reported EPS of -$0.83 beating consensus estimates of -$0.99 and a solid cash runway—recent operational updates included inducement grants to new hires on April 3 under Nasdaq rules, signaling team expansion amid growth. Investor conferences in March, such as Leerink Global Healthcare, highlighted nex-z progress in partnership with Regeneron Pharmaceuticals, where costs are shared. No major macroeconomic pressures or sector-wide downturns directly hit NTLA recently; instead, biotech sentiment improved on gene therapy tailwinds.
Price behavior linked closely to these events: post-FDA news, shares jumped, with elevated volumes persisting into April amid broader YTD gains exceeding 50%. Short interest remains high at ~35% of float, adding volatility but also rebound potential on positive data. Overall, these developments shifted sentiment from prior safety jitters to pipeline validation, driving the recent upcycle.
2026 Outlook and Key Factors to Monitor
2026 represents a transformative year for Intellia Therapeutics, with multiple Phase 3 readouts anticipated across its CRISPR pipeline. Key programs like nex-z for ATTR amyloidosis and lonvo-z for hereditary angioedema (in partnership with Regeneron) could deliver pivotal efficacy and safety data, potentially supporting regulatory filings. HAELO Phase 3 for angioedema and ex vivo efforts in oncology and autoimmune diseases further diversify opportunities. Investors should track clinical milestones, including enrollment progress and interim results, alongside cash burn rates—bolstered by recent financials but pressured by R&D investments.
Risks include trial delays, competitive pressures from peers like CRISPR Therapeutics, and regulatory hurdles in gene editing. Opportunities lie in platform expansions, such as modular in vivo capabilities, and potential partnerships. Macro factors like biotech funding environments and reimbursement landscapes for one-time therapies will influence trajectory. Strategic cost management and intellectual property defenses remain critical as Intellia advances toward commercialization.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
NTLA sees its Stochastic Oscillator recovers from oversold territory
On May 04, 2026, the Stochastic Oscillator for NTLA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 08, 2026. You may want to consider a long position or call options on NTLA as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
NTLA moved above its 50-day moving average on May 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 130 cases where NTLA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for NTLA moved out of overbought territory on April 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for NTLA turned negative on April 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on May 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NTLA broke above its upper Bollinger Band on April 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.245) is normal, around the industry mean (32.489). P/E Ratio (0.000) is within average values for comparable stocks, (51.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.680). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (26.247) is also within normal values, averaging (337.233).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary, potentially curative therapeutics
Industry Biotechnology